Understanding of the mechanisms by which FGF/FGFR3 and CNP/NPR2 regulate longitudinal bone growth has allowed the development of an effective therapeutic strategy using a CNP analog (vosoritide; BMN-111) to treat ACH (33, 34). This evidence concerns the gene FGFR3 and achondroplasia.